InferRead Lung CT.AI is designed to support concurrent reading and is designed to aid radiologists in pulmonary nodule detection during the review of chest computed tomography (CT) scans, increasing accuracy and efficiency.

August 4, 2020 — Infervision received U.S. Food and Drug Administration (FDA) 510(K) clearance of the InferRead Lung CT.AI product, which uses the state-of-the-art artificial intelligence and deep learning technology, to automatically perform lung segmentation, along with accurately identifying and labeling nodules of different types. InferRead Lung CT.AI is designed to support concurrent reading and is designed to aid radiologists in pulmonary nodule detection during the review of chest computed tomography (CT) scans, increasing accuracy and efficiency.

With five years of international clinical use, Infervision’s InferRead Lung CT.AI application is a robust and powerful tool to serve the radiologist.

InferRead Lung CT.AI is currently in use at over 380 hospitals and imaging centers globally. More than 55,000 cases daily are being processed by the system, and over 19 million patients have already benefited from this advanced AI technology. “Fast, workflow friendly, and accurate are the three key areas we have emphasized during product development. We’re excited to be able to make our InferRead Lung CT.AI solution available to the North American market. Our clients tell us it has great potential to help provide improved outcomes for providers and patients alike,” said Matt Deng, Ph.D., director of Infervision North America. The Company offers the system under a number of pricing options to meet everyone’s needs.

The company also predicts the system may also be of great benefit to lung cancer screening (LCS) programs across the nation. Lung cancer is the second most common cancer in both men and women in the U.S. It might have around a 60% 5-year survival rate if discovered at the early stage. However, the survival rate is lower than 10% if progressed to the later stages without timely follow-up and treatment.

The Lung Cancer Screening program has been designed to encourage the early diagnosis and treatment of the high-risk population meeting certain criteria. The screening process involves low-dose CT (LDCT) scans to determine any presence of lung nodules or early-stage lung disease. However small nodules can be very difficult to detect. Missed diagnoses are not uncommon. “The tremendous potential for lung cancer screening to reduce mortality in the U.S. is very much unrealized due to a combination of reasons.  Based on our experience reviewing the algorithm for the past several months and my observations of its extensive use and testing in China, I believe that Infervision’s InferRead Lung CT.AI application can serve as a robust lung nodule “spell-checker” with the potential to improve diagnostic accuracy, reduce reading times, and integrate with the image review workflow,” said Eliot Siegel, M.D., professor and vice chair of research information systems in radiology at the University of Maryland School of Medicine.

InferRead Lung CT.AI is now FDA cleared, and has also received the CE mark in Europe. “This is our first FDA clearance for the deep-learning-based chest CT algorithm and it will lead the way to better integration of advanced A.I. solutions to help the healthcare clinical workflow in the region,” according to Deng, “This marks a great start in the North American market, and we are expecting more high-performance AI tools in the near future.”

For more information: us.infervision.com

 

Related Content

News | Ultrasound Imaging

May 24, 2022 — Mindray, a global leader and developer of healthcare technologies and solutions for ultrasound, patient ...

Time May 24, 2022
arrow
News | Coronavirus (COVID-19)

May 24, 2022 — A special type of MRI found lung abnormalities in patients who had previously had COVID-19, even those ...

Time May 24, 2022
arrow
News | Radiology Business

May 23, 2022 — AHRA, The Association for Medical Imaging Management, the professional organization representing all ...

Time May 23, 2022
arrow
News | Coronavirus (COVID-19)

May 23, 2022 — The clinical and imaging characteristics of COVID-19 breakthrough infections in fully vaccinated patients ...

Time May 23, 2022
arrow
News | Lung Imaging

May 23, 2022 — Xoran Technologies announced they have completed Phase 1 for their NHLBI grant for mobile lung CT. Just ...

Time May 23, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Breast Imaging

May 18, 2022 — Therapixel, a company leading the use of AI-based software for women’s health, announces it has released ...

Time May 18, 2022
arrow
Feature | Radiology Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Time May 18, 2022
arrow
Feature | Coronavirus (COVID-19)

Clinical scientists used machine learning (ML) models to explore de-identified electronic health record (EHR) data in ...

Time May 18, 2022
arrow
News | Digital Pathology

May 17, 2022 — Proscia, a leader in digital and computational pathology solutions, has introduced an automated quality ...

Time May 17, 2022
arrow
Subscribe Now